



Company Announcement no. 18/2008

To: OMX Nordic Exchange Copenhagen

Hørsholm, Denmark, April 17, 2008

Major shareholder announcements

Hørsholm, Denmark, 17 April 2008; LifeCycle Pharma A/S (OMX: LCP) today announced that LCP has received a notice that Novo A/S has increased their holdings of LCP shares from 4,096,416 to 11,628,269 shares, corresponding to 20.73 % of the shares in LCP.

About LifeCycle Pharma A/S (“LCP”)

LCP is an emerging specialty pharmaceutical company that, through innovative technologies, is able to rapidly develop a portfolio of differentiated products to meet the unique needs of key therapeutic markets and patient populations. This includes products for immunosuppression, specifically organ transplantation, and to combat certain cardiovascular diseases. By using its unique and patented delivery technology, MeltDose[®], LCP is able to develop drugs with enhanced absorption and thereby increased bioavailability. LCP has a cholesterol lowering product, Fenoglide[™], currently on the U.S. market and a diversified near- and medium-term pipeline, including five product candidates in clinical trials and three in preclinical stages of development. LCP is listed on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX: LCP).

For further information please contact LifeCycle Pharma A/S:

Hans Christian Teisen

Executive Vice President & CFO

+45 20 30 69 85;

E-mail: hct@lcpharma.com

LIFECYCLE PHARMA A/S
KOGLE ALLÉ 4
DK-2970 HØRSHOLM
WWW.LIFECYCLEPHARMA.COM

TEL. +45 7033 3300
FAX +45 3613 0319
CVR. 26 52 77 67
INFO@LCPHARMA.COM

page 1 of 1